A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
暂无分享,去创建一个
M. Ladanyi | A. Drilon | M. Kris | M. Arcila | Gregory Riely | R. Somwar | J. Hechtman | B. Druker | M. Davare | Roger S Smith | T. O'hare | C. Eide | N. Vellore | M. Zabriskie | Lu Wang | Jacob P. Wagner
[1] 송안아. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer , 2016 .
[2] A. Drilon,et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors , 2015, Proceedings of the National Academy of Sciences.
[3] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[4] C. Tognon,et al. Detecting and targetting oncogenic fusion proteins in the genomic era , 2015, Biology of the cell.
[5] Roman K. Thomas,et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. McTigue,et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.
[7] Dong-Wan Kim,et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[8] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[9] J. Engelman,et al. Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer , 2014, Clinical Cancer Research.
[10] L. Norton,et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.
[11] Daniel R Roe,et al. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.
[12] William Pao,et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Renee Emkey,et al. The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase* , 2012, The Journal of Biological Chemistry.
[14] T. Gu,et al. Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.
[15] Jeffrey W. Clark,et al. ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[17] William Pao,et al. ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.
[18] J. Christensen,et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.
[19] J L Sebaugh,et al. Guidelines for accurate EC50/IC50 estimation , 2011, Pharmaceutical statistics.
[20] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[21] T. Cheatham,et al. Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.
[22] William Pao,et al. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.
[23] Sungjoon Kim,et al. Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.
[24] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[25] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[26] Nathan A. Baker,et al. Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Klein,et al. Constant pressure molecular dynamics algorithms , 1994 .
[28] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[29] P. Kollman,et al. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .
[30] B. Brooks,et al. An analysis of the accuracy of Langevin and molecular dynamics algorithms , 1988 .
[31] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .